## JANUARY 2014 

## Cumberland begins promotion and distribution of Omeclamox ® -Pak 

Cumberland’s field sales force begins promoting Omeclamox-Pak to gastroenterologists across the nation. 

## MARCH 2014 

## Cumberland announces acquisition of Vaprisol ®  from Astellas Pharma 

Cumberland acquires all assets and assumes full responsibility to market, distribute and manufacture Vaprisol. 

## MARCH 2014 ® 

## Caldolor  reduces fever in pediatric patients 

Data from a pediatric study demonstrates the safety and efficacy of Caldolor in reducing fever in hospitalized children. Caldolor is associated with statistically significant reduction in temperature within the first two hours of dosing. 

## MAY 2014 

## Cumberland reports return to profitability 

In its first quarter earnings release, Cumberland reports its return to profitability through growth in sales of established brands and the addition of new product sales. 

## international partner. 2014 Milestones 

## MAY 2014 

## Cumberland and Gloria Pharmaceuticals announce joint research and development investment 

China’s Gloria Pharmaceuticals and Cumberland together invest $2 million in Cumberland Emerging Technologies to accelerate the development of new product candidates from regional research centers. CET is majority owned by Cumberland in partnership with Vanderbilt University, the state of Tennessee and Gloria – our new 

## MAY 2014 

## Cumberland launches Vaprisol ® promotion 

Cumberland launches active sales and marketing campaign to support Vaprisol. 

## OCTOBER 2014 ® 

## Caldolor  improves recovery in adult surgery patients 

Results from an investigator study show preoperative intravenous ibuprofen improved the overall quality of recovery including comfort, emotion and pain in patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery. 

